- Sanofi Pasteur’s dengue vaccine, approved in El Salvador in February, is now available in private immunization clinics throughout the country -
- The nation’s health care professionals welcome the ability to prevent dengue hospitalizations and severe disease amongst their patient populations with this new clinical prevention tool against dengue -

El Salvador, San Salvador – July 27, 2016 – Sanofi Pasteur, the vaccines division of Sanofi, announced today that its new dengue vaccine can now be administered by healthcare professionals in El Salvador, as the first clinical preventive tool against dengue. 

People in El Salvador can be vaccinated against dengue during medical consultation with their healthcare providers including pediatricians, internists, and primary care doctors.

At a medical event held by Sanofi Pasteur in collaboration with the Scientific Society of Internal Medicine, the Scientific Society of Infectiology, and the Scientific Society of Pediatrics of El Salvador, the dengue vaccine was recognized as a crucial new clinical tool in the integrated efforts towards dengue prevention in the country. “By vaccinating our patients against dengue, we anticipate being able to prevent thousands of ambulatory cases, hospitalizations and deaths due to dengue infection every year,” noted Mario Gamer, President of the Salvadorian Association of Infectiology and member of the Pediatrician Society of El Salvador.

The tetravalent vaccine of Sanofi Pasteur was approved on February 5th, 2016 in El Salvador to provide protection against all four types of dengue for people 9 to 45 years of age. A summary of the efficacy profile of the vaccine in study participants 9 years of age and older showed that the Sanofi Pasteur dengue vaccine prevents 65.6% of all dengue cases with higher efficacy up to 80% against hospitalizations due to dengue and 93% protection against severe dengue cases, including dengue hemorrhagic fever that can cause death.1

Sixty percent of dengue cases in El Salvador are reported in individuals older than 9 years of age, who represent a highly mobile and socially-active segment of the community with the potential to contribute significantly to spread of the disease throughout the country.2

Dengue incidence has risen sharply in El Salvador in the last decade, reaching more than 50,000 suspected cases in 2015 with an incidence rate of approximately 800 cases per 100.000 inhabitants. Last year, El Salvador experienced its second largest outbreak of dengue since 1995.3

In April 2016, the Strategic Advisory Group of Experts (SAGE) on immunization to the World Health Organization (WHO) positively endorsed use of Dengvaxia® in highly endemic countries and recommended that these countries consider introducing the dengue vaccine as part of an integrated disease prevention plan to reduce their dengue burden.4 The WHO has set the objectives of reducing dengue mortality by dengue by 50% and morbidity by 25% by 2020 in the endemic countries.5